CNR1 and neoplasm: In this context, the association we found between tumor size/renal decline and systemic 2-AG, a full agonist of CB1R and CB2R, warrants further interest in the ECS mediation of the RCC progression, pointing to the rationale of considering systemic 2-AG as a biomarker for RCC.